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The Roie of Comparative Effectiveness Research
in Medicine and Heaith
AislingR. Caffi-ey, PhD, MS
TODAY, MORE THAN EVER, HEALTHCARE
systems need to do more with less.
Clinicians, decision-makers, and other
stakeholders are seeking evidence-based
healthcare practices that control expen-
ditures while improving patient care. Of
particular concern is the paucity of sup-
portive clinical data related to alternative
therapeutic options for the treatment
of acute and chronic conditions. The
demand for high-quality pharmacoepide-
miologic and pharmacoeconomic research
is at unprecedented levels, with govern-
ment agencies, foundations, and private
industry collectively committing billions
of dollars in funding for studies examining
the beneficial and unintended effects of
medications.''^ Pharmacoepidemiology
provides vital insights into effectiveness
and safety, while pharmacoeconomics
addresses value and costs given limited
healthcare resources.
WHAT is COMPARATÍVE
EFFECTIVENESS RESEARCH?
Ofi:en, the selection of the most appro-
priate treatment is complicated by limited
efficacy, effectiveness, and safety data. In
efficacy trials, the capability to produce
the planned effect under ideal conditions
is typically assessed in an active study drug
compared to a placebo comparator. Alter-
natively, comparative effectiveness focuses
on head-to-head comparisons between
two or more active treatments in the real-
world clinical setting. "While randomized
controlled trials provide evidence for the
drug approval process, there is a lack of
comparative data on which agents produce
the most favorable clinical outcomes with
the fewest side effects in various real-world
clinical populations. Realizing the need for
evidence supporting prescribing decisions
and the importance of comparative effec-
tiveness research, programs developed un-
der the 2009 American Reinvestment and
Recovery Act and 2010 Patient Protection
and Affordable Care Act, as well as initia-
tives from other public and private agencies,
have sought to fill critical gaps in knowledge
regarding best treatment practices.
STUDY DESIGNS AND CAUTIONS
OF COMPARATIVE EFFECTIVENESS
RESEARCH
Comparative effectiveness research
can be carried out with various study
designs including clinical trials and obser-
vational studies, as well as meta-analyses
and systematic reviews. Study design
selection depends on the research ques-
tion, exposure prevalence, primary and
secondary outcomes, data availability,
existing knowledge, costs, and limita-
tions of each design. One of the greatest
challenges for comparative effectiveness
clinical trials and observational studies
relates to the comparability of patients
in different treatment groups. Confound-
ing by indication is a primary concern
in comparative effectiveness research.
The likelihood of receiving different
drugs directly relates to the indication
for treatment, patient characteristics,
provider characteristics, and facility
characteristics which can confound the
observed relationship between exposure
and outcome.' Further, it is often dif-
ficult to conceptualize and define these
potential external influences.
Often, the
selection of the
most appropriate
treatment is
complicated by
limited efficacy,
effectiveness, and
safety data.
Clinical trials rely on randomization
to balance baseline patient characteristics
between study drugs. Whereas observa-
tional studies use analytic techniques and
other study design approaches to mitigate
the impact of confounding by evenly
distributing significant variables associ-
ated with the exposure and outcome.'
Randomization is considered the gold
standard approach to balancing patient
characteristics, including both measured
and, more importantly, unmeasured
confounders, in order to evaluate the
impact of treatment on the study end-
points. However, residual confounding
can occur through the omission of a key
confounder analytically or in cases of
randomization failure. Indeed, subgroup
analyses are highly criticized as the effects
of randomization may have failed in the
subgroups assessed, resulting in analyses
of nonrandomized data.
Imbalance in clinically significant
variables can bias the results of both
clinical trials and observational studies.
Usually it is difficult to assess whether
these variations were due to chance or
selection bias, particularly when sta-
tistically significant differences remain
after randomization in clinical trials or
analytic adjustment in observational
studies. Such variations may indicate
residual confounding, for example, if
additional differences existed between
treatment groups in variables that were
not assessed (unmeasured confounders),
or may even indicate effect modification.
When significant baseline imbalances
are observed between treatment groups,
regardless of study design, assessments
of residual confounding should be
completed.
In general, the resources required
for large clinical trials, particularly those
powered to detect superiority, are cost
prohibitive and patient enrollment can
be slow. Additionally, non-inferiority is
easier to detect than superiority. Due to
these limitations, there may be reluctance
to fund head-to-head active comparator
trials. A major strength of observational
comparative effectiveness research is that
it uses existing data to discern important
real-world differences in effectiveness
and safety. To improve the efficiency of
comparative effectiveness clinical trials,
observational research can be used to
guide the development and design of
randomized trials.
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COMPONENTS OF A SUCCESSFUL
COMPARATIVE EFFECTIVENESS
RESEARCH PROGRAM
Properly designed, conducted, and
interpreted comparative effectiveness re-
search can provide evidence-based knowl-
edge for clinical decision-making that
optimizes patient outcomes. As research-
ers and consumers of healthcare research,
the best resources for comparative effec-
tiveness technical reports and methods
guides include the Agency for Healthcare
Research and Quality Effective Healthcare
Program, the Institutes of Medicine, the
Patient-Centered Outcomes Research
Institute, and the National Information
Center on Health Services Research and
Health Care Technology. Other resources
that assist in the critical evaluation ofthe
literature include the GRACE principles,
Cood Research Practices for Comparative
Effectiveness Research from the Interna-
tional Society for Pharmacoeconomics
and Outcomes, and the Cuidelines for
Good Pharmacoepidemiology Prac-
tices from the International Society for
Pharmacoepidemiology.''"''
For comparative effectiveness re-
search, a strong, interdisciplinary research
team is needed, and core contributors
should include physicians, pharmacists,
and pharmacoepidemiologists. Also,
patients are increasingly recognized as
key stakeholders in designing clinical
research.^  With the tremendous growth
in health outcomes and health econom-
ics, there is record demand for trained
professionals in these fields, though few
universities in the country offer such
programs. The Program in Pharmacoepi-
demiology and Pharmacoeconomics of
the University of Rhode Island College
of Pharmacy engages in the focused,
interdisciplinary training of the next
generation of pharmacoepidemiologists
and pharmacoeconomists.
My research program has focused on
the comparative effectiveness of antimi-
crobials for the treatment of infectious
diseases.^  The goal of this research is to
provide insight into the optimal treat-
ments for invasive infections, enhancing
patient safety by reducing treatment
failures and adverse outcomes, through
the use of rich data sources and sophis-
ticated analytical techniques.*' To ad-
dress potential biases, the most accurate
sources available for defining exposures,
outcomes, and potential confounders
are used, including pharmacy data, mi-
crobiology data, laboratory results, and
records of inpatient and outpatient care
from electronic medical records. Further,
we utilize advanced statistical methods,
including propensity scoring, calibration,
and assessments of residual confounding,
to mitigate confounding and achieve bal-
ance between treatment groups.
In summary, with the proper study
team, study design, study methods,
and resources, comparative effective-
ness research plays an important role
in evidence-based medicine. Evidence-
based pharmacotherapy is necessary for
maximizing positive clinical outcomes
and minimizing negative effects to better
inform and improve clinical practice.
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